Paysign/$PAYS
1D1W1MYTD1Y5YMAX
Capital at risk
About Paysign
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.
- Ticker
- $PAYS
- Sector
- Finance
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Henderson, United States
- Website
- www.paysign.com
Paysign Metrics
BasicAdvanced
$729M
49.90
$0.26
0.76
-
Price and volume
Market cap
$729M
Beta
0.76
52-week high
$14.43
52-week low
$3.08
Average daily volume
746K
Financial strength
Current ratio
1.139
Quick ratio
0.527
Long term debt to equity
0.08
Total debt to equity
0.095
Profitability
EBITDA (TTM)
27.108
Gross margin (TTM)
61.00%
Net profit margin (TTM)
15.67%
Operating margin (TTM)
15.78%
Effective tax rate (TTM)
21.58%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
3.88%
Return on equity (TTM)
30.82%
Valuation
Price to earnings (TTM)
49.896
Price to revenue (TTM)
7.069
Price to book
12.11
Price to tangible book (TTM)
20.92
Price to free cash flow (TTM)
10.53
Free cash flow yield (TTM)
9.50%
Free cash flow per share (TTM)
1.226
Growth
Revenue change (TTM)
46.84%
Earnings per share change (TTM)
115.66%
3-year revenue growth (CAGR)
33.40%
10-year revenue growth (CAGR)
27.66%
3-year earnings per share growth (CAGR)
135.38%
10-year earnings per share growth (CAGR)
17.84%
What the Analysts think about Paysign
Analyst ratings (Buy, Hold, Sell) for Paysign stock.
Analyst projections of the future price of Paysign stock.
Bulls say / Bears say
Second-quarter revenue rose 48.1% year on year to $28.3m, led by an 88.9% increase in pharma revenue. Paysign added 51 net patient-affordability programmes in 12 months and processed claims rose about 54%, showing strong demand for its higher-growth business. (Paysign)
Management raised 2026 guidance to $114m–$117m of revenue and $35m–$38m of adjusted EBITDA, while forecasting gross margins of 62%–63%. The upgrade suggests that the mix shift towards patient affordability is creating meaningful operating leverage. (Paysign)
The plasma business is recovering: second-quarter revenue increased 21.4% despite 46 fewer centres than a year earlier. Revenue per centre and average loads per centre both improved, indicating better utilisation of the remaining network. (Paysign, Financial Times)
Plasma growth is partly offset by a shrinking customer base: Paysign exited the second quarter with 561 centres, down 46 year on year. The company said closures and a customer sale to a rival provider drove the decline, highlighting switching and competitive risk. (Paysign)
Customer concentration remains material. One pharma patient-affordability customer accounted for 36% of accounts receivable at 30 June 2026, so a payment delay or deterioration in that relationship could affect liquidity and working capital. (StockTitan)
The full-year GAAP net-income outlook includes a non-recurring, non-cash $990,000 benefit from eliminating the Gamma acquisition earn-out liability. That makes reported profit look stronger than underlying recurring earnings, even though adjusted EBITDA excludes the benefit. (Last10K)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
Paysign Financial Performance
Revenues and expenses
Paysign Earnings Performance
Company profitability
Upcoming events
No upcoming events
Paysign News
AllArticlesVideos
Funds containing Paysign
Fund name | Fund size | $PAYS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.